Cantabio Pharmaceuticals

05/03/2022

Novel technologies developed by to quantifying various redox forms of the DJ-1 protein for early diagnosis of disease is presented by the company's CEO, Dr. Toth, at conference in London on April 4, 2022. https://www.oxfordglobal.co.uk/biomarkers-series-uk/

01/06/2022

Cantabio Pharmaceuticals awarded major grant from The Michael J. Fox Foundation to develop novel small-molecule aggregation inhibitors of the tau protein for the treatment of Parkinson’s disease https://www.accesswire.com/viewarticle.aspx?id=681098

03/12/2021

's CEO, Dr. Toth, is presenting novel findings on therapeutic strategies targeting the DJ-1 protein misfolding linked to the onset of disease at the Targeting Protein Misfolding Congress on March 15, 2021 https://www.kisacoresearch.com/events/targeting-protein-misfolding-congress

10/27/2020

Cantabio's CEO, Dr. Toth, is presenting novel findings on targeting the intrinsically disordered state of proteins as a therapeutic strategy against diseases such as Alzheimer's & Parkinson's, and is also part of a panel discussing Strategic Analysis of Protein Misfolding Therapeutics at The Protein Misfolding Drug Discovery Summit on October 29, 2020.

09/23/2020

It is World Alzheimers's month! Cantabio is developing novel disease modifying therapeutics for disease.

09/17/2020

Cantabio receives grant from Michael J. Fox Foundation to develop new detection technologies for DJ-1 protein to create a novel much needed biomarker for the potential early diagnosis and tracking of the progression of disease. https://www.accesswire.com/606377/Cantabio-Pharmaceuticals-receives-grant-from-Michael-J-Fox-Foundation-to-develop-a-novel-DJ-1-protein-based-biomarker-for-Parkinsons-Disease

07/23/2020

Recent publication in Annals of Neurology report patient with previously unknown homozygous mutation in DJ-1 protein highlighting its importance in the on-set of .

Studies of the phenotype and population distribution of rare genetic forms of parkinsonism are required, now that gene‐targeting approaches for Parkinson's disease have reached the clinical trial sta...

06/10/2020

FDA approves Tauvid™, the first novel PET imaging agent for the detection of tau protein tangles, an important pathological marker of tauopathies such as and , for aiding the diagnosis and progression of .
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease

02/28/2020

There is always challenge to fill up clinical trials for . 85 percent of trials face delays and 30 percent never get off the ground because of a lack of volunteers, resulting in a dramatic slowdown in progress toward a cure. Please join now!

The new Fox Trial Finder makes it easy for participants to find clinical studies they may be eligible to join and instantly connect with research teams.

02/26/2020

Cantabio's CEO Dr Gergely Tóth to present novel findings on the company’s therapeutic programs on DJ-1 and Tau for and at AAT-AD/PD Focus Meeting 2020 in Vienna.

12/04/2019

New study describes the discovery of novel small molecule drug candidates that target α-synuclein and protect in cellular models, first authored by Cantabio's CEO Dr Gergely Tóth in Nature's Scientific Reports:

The over-expression and aggregation of α-synuclein (αSyn) are linked to the onset and pathology of Parkinson’s disease. Native monomeric αSyn exists in an intrinsically disordered ensemble of interconverting conformations, which has made its therapeutic targeting by small molecules highly chall...